BIOAFFINITY TECHNOLOGIES, INC. Financials bioAffinity Technologies, Inc.
Equities
BIAF
US09076W1099
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.4 USD | -0.83% |
|
-10.11% | +63.21% |
| May. 15 | BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 15 | Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $2.4M | MT |
Valuation
| Fiscal Period: December | 2022 | 2024 |
|---|---|---|
| Capitalization 1 | 13.39 | 27.63 |
| Enterprise Value (EV) 1 | 13.39 | 27.63 |
| P/E ratio | -0.88 x | -2.53 x |
| Yield | - | - |
| Capitalization / Revenue | 2,789,916,667 x | - |
| EV / Revenue | 2,789,916,667 x | - |
| EV / EBITDA | - | - |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Price to Book | - | - |
| Nbr of stocks (in thousands) | 8,370 | 11,514 |
| Reference price 2 | 1.600 | 2.400 |
| Announcement Date | 3/31/23 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2024 |
|---|---|---|
| Net sales | 0.0048 | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | -8.154 | - |
| Net margin | -169,877.29% | - |
| EPS 1 | -1.810 | -0.9500 |
| Free Cash Flow | - | - |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 3/31/23 | - |
1USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | 9.92 | 10 | - | - |
| Net Cash position 1 | - | - | 11.2 | 1.24 |
| Leverage (Debt/EBITDA) | -3.843 x | -4.543 x | - | - |
| Free Cash Flow | - | -0.86 | -3.41 | -3.61 |
| ROE (net income / shareholders' equity) | - | 55.6% | 2,320% | -99.8% |
| ROA (Net income/ Total Assets) | - | -173% | -36.8% | -48.8% |
| Assets 1 | - | 3.667 | 22.18 | 16.25 |
| Book Value Per Share 2 | -5.630 | -5.900 | 1.320 | 0.5200 |
| Cash Flow per Share 2 | 0.0300 | 0.5100 | 1.360 | 0.3000 |
| Capex 1 | 0 | - | 0.22 | 0.02 |
| Capex / Sales | - | - | 4,580.2% | 0.9% |
| Announcement Date | 4/25/22 | 4/25/22 | 3/31/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +63.21% | 27.63M | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B |
- Stock Market
- Equities
- BIAF Stock
- Financials bioAffinity Technologies, Inc.
